He spent twenty years inside the giants of medtech so he could finally build the thing they wouldn't: a soft sticker that reads your blood pressure, beat by beat, with no cuff and no needle.
The cuff on your arm hasn't really changed since your grandparents' day. It squeezes, it beeps, it hands you two numbers, and then it forgets you. Ray Liu's quarrel with that machine is simple: your blood pressure does not hold still for the photograph. It rises when you stand, dips when you sleep, spikes when you stop breathing. A cuff gives you a snapshot of a thing that is, by nature, a movie.
Vena Vitals, the company Liu runs as CEO and co-founder, makes the movie. The product is a soft, skin-like patch that sticks on like a bandage and senses the faint drumbeat of blood pushing through an artery. Each pulse presses the sensor; the sensor answers with a signal. Pressure climbs, the signal swells. Pressure falls, it softens. Algorithms turn that rise and fall into a continuous read - the kind of real-time tracking that, until now, required a needle threaded into an artery.
That needle has a name in hospitals: the arterial line. It is accurate, it is the gold standard, and it is the thing nobody volunteers for. In operating rooms across the country, Vena Vitals has put its sticker beside the arterial line on more than 600 patients and watched the two readings move together, almost perfectly, through the violent pressure swings of surgery. One sticker. A fraction of the cost. No puncture.
Liu did not arrive at this by accident. He is an engineer who learned to sell, a labmate who became a CEO, and a man who waited two decades for the right material and the right people to show up at the same time.
Back in 2002, Liu was a National Science Foundation fellow at Berkeley's Sensor and Actuator Center, building the theory for transistors that could sense strands of DNA. In that lab he met Michelle Khine. Then their paths split the way young scientists' paths do - she went deeper into material science, he went out into industry.
Industry, for Liu, meant the big rooms. Global product surveillance at GE Healthcare. A stint consulting under the Siemens banner. Product and strategy work at Socialwellth and at Vizient, with two health-tech exits along the way. He picked up the unglamorous, decisive skill that kills most medical-device dreams: how to actually get something past the FDA. Somewhere in there he added a Harvard MBA, because an engineer who can also read a term sheet is a dangerous thing.
Khine, meanwhile, had become a professor at UC Irvine and a serial inventor - the kind known for prototyping devices out of children's shrink plastic. With her PhD student Josh Kim, lead author on the seminal papers, she spent roughly eight years coaxing a stretchable, skin-like sensor out of the lab. The science was real. What it needed was someone who knew how to turn a paper into a product.
In 2019 the old labmates reconnected. Khine and Kim had the material. Liu had the map. Vena Vitals was born in Irvine, and the founding triangle was complete: the inventor, the scientist, the operator.
Think of it as a stethoscope for pressure - one that never lifts off your skin.
Blood pushes through the artery just under the skin. Each beat presses against the soft sensor sitting on top of it.
Pressure up, the signal grows. Pressure down, the signal fades. The waveform mirrors the artery, beat for beat.
Proprietary algorithms translate that rise and fall into continuous, clinical-grade numbers - over Bluetooth, to a tablet.
Builds theory for DNA-sensing transistors at the Berkeley Sensor and Actuator Center. Meets a labmate named Michelle Khine.
Global product surveillance, then management consulting. Learns how big medtech ships - and how it doesn't.
Adds the language of business to the language of engineering.
Head of product and business development. A digital-health exit.
Senior director of product strategy at one of healthcare's largest member networks. Exit number two.
Reunites with Khine, teams with Josh Kim, and takes the CEO seat in Irvine.
Joins the Summer 2020 batch; MedTech Innovator and EvoNexus follow.
Sensor validated against arterial lines in 600+ patients; clearance for hospital use targeted this year.
Our blood pressures are constantly changing, but we only get snapshots in time - using uncomfortable cuff compressions, or risky invasive procedures.
We're the first and only technology that can quantify the magnitude of blood pressure spikes immediately after apneic events.
He started his career simulating DNA-sensing transistors - then walked off the lab bench and into the boardroom.
Three degrees, three schools: Illinois for engineering, Berkeley for biosensing, Harvard for the MBA.
In trials the patch rode on patients' feet, streaming pressure over Bluetooth while surgeons worked.
Nine of fourteen teammates are UC Irvine alumni. Five of them hold PhDs. The lab never really left.